II. Pending Claims

1. (Previously Presented) A pharmaceutical composition comprising:

(a) a cyclodextrin; and

(b) a lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.

2. (Previously Presented) The pharmaceutical composition of claim 1 which further comprises water.

3. (Previously Presented) The pharmaceutical composition of claim 1 which is a powder.

4. (Previously Presented) The pharmaceutical composition of claim 1 which is a lyophilized powder.

5. (Previously Presented) A pharmaceutical composition comprising:

(a) an aqueous cyclodextrin carrier and

(b) a therapeutically effective amount of a lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.

6. (Previously Presented) The pharmaceutical composition of Claim 5, wherein the pharmaceutical composition comprises:

(a) a therapeutically effective amount of a lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof;

(b) 1 to 40 weight percent of a cyclodextrin; and

(c) 60 to 99 weight percent of water, provided that the components of the composition total 100 weight percent.

7. (Original) The pharmaceutical composition of Claim 5, wherein the cyclodextrin is

hydroxypropyl-β-cyclodextrin or sulfobutyl ether β-cyclodextrin.

8. (Original) The pharmaceutical composition of Claim 7, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

9. (Original) The pharmaceutical composition of Claim 6, wherein the cyclodextrin comprises about 5 to 35 weight percent of the composition.

10. (Original) The pharmaceutical composition of Claim 9, wherein the cyclodextrin comprises about 10 to 30 weight percent of the composition.

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Withdrawn) A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a pharmaceutical composition of claim 1.

15. (Withdrawn) A method of treating a bacterial disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof in combination with a cyclodextrin.

16. (Withdrawn) A method for reducing tissue accumulation of a lipidated glycopeptide antibiotic when administered to a mammal, the method comprising administering the lipidated glycopeptide antibiotic to the mammal in a pharmaceutical composition comprising a cyclodextrin and a therapeutically effective amount of the lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.

17. (Withdrawn) A method for reducing nephrotoxicity produced by a lipidated glycopeptide antibiotic when administered to a mammal, the method comprising administering the lipidated glycopeptide antibiotic to the mammal in a pharmaceutical composition comprising a cyclodextrin and a therapeutically effective amount of the lipidated glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.

18. (Canceled)

19. (Canceled)